Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider

NEXT STORY
SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX® 
PREV STORY
BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020

author_avatar
NASDAQ Market News

Chembio Diagnostics and Massachusetts General Hospital Enter Memorandum Of Understanding to Develop Point-of-Care Fever Diagnostic Test

MEDFORD, N.Y., May 22, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader ...

author_avatar
NASDAQ Market News

Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA

author_avatar
NASDAQ Market News